Status:
COMPLETED
To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Healthy
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood concentration of liraglutide (pharmacokinetics) as well as the effects on glucose and insulin (pharmacodynam...
Eligibility Criteria
Inclusion
- Informed consent obtained before any trial related activities
- Healthy Chinese male subjects
- Body mass index (BMI) between 19.0 and 27.0 kg/m2 (both inclusive)
- Fasting plasma glucose less than 6.0 mmol/L
- Non-smoker
Exclusion
- Clinically significant abnormalities on pre-study clinical examination or any laboratory measurements during screening (any abnormality should be discussed with the clinical monitor)
- Presence of diabetes, cancer or any clinically significant cardiac, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, dermatological, venereal, haematological, neurological, or psychiatric diseases or disorders
- Blood pressure in supine position at the screening, after resting for 5 min, outside the ranges 90- 140 mmHg systolic and/or 40 - 90 mmHg diastolic
- Pulse in supine position at the screening, after resting for 5 min, outside the range 40 - 100 times/min
- Hepatitis B surface antigen, Hepatitis C antibodies or HIV antibodies positive.
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT00761540
Start Date
October 1 2008
End Date
December 1 2008
Last Update
January 26 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China, 100032